• The basal ganglia can either promote or inhibit movement, depending on the dopamine innervation of the striatum1,2
  • Normal movement is dependent on appropriate dopamine production by SNc neurons innervating the striatum1,2
    • To facilitate this movement, the striatum receives dopaminergic motor input from the cortex 
    • The striatum sends this signal further, after modulation by the SNc (either excitatory as a result of dopamine D1 receptor activation, or inhibitory, as a result of dopamine D2 receptor activation) 
    • The signal is then sent through direct and indirect pathways to the GPi segment 

GPi=globus pallidus internus; SNc=substantia nigra pars compacta 

file_download Download in HQ

Related content

image Image Graphic showing extracellular, multimerization, and intracellular targets of alpha-synuclein for therapeutic intervention in Parkinson’s disease
Possible α-synuclein targets for development of therapies for Parkinson’s disease

Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease

26.06.2025 Parkinson’s Disease
image Image Chart showing progression of functional decline in Parkinson’s disease with different treatment approaches, from symptomatic benefit to disease modification.
Disease modification in Parkinson’s disease

Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure

26.06.2025 Parkinson’s Disease
image Image Diagram showing how COMT inhibitors block the conversion of L-DOPA to 3-OMD, enhancing dopamine levels in the synapse in Parkinson’s disease.
Catechol-O-methyltransferase (COMT) inhibitors mechanism of action

Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA

26.06.2025 Parkinson’s Disease